Weekly Analysts’ Ratings Changes for Cytokinetics (CYTK)

A number of research firms have changed their ratings and price targets for Cytokinetics (NASDAQ: CYTK):

• 12/22/2025 – Cytokinetics was given a new $84.00 price target on by analysts at Truist Financial Corporation.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Morgan Stanley from $65.00 to $71.00. They now have an “overweight” rating on the stock.
• 12/22/2025 – Cytokinetics was given a new $83.00 price target on by analysts at Leerink Partners.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Royal Bank Of Canada from $87.00 to $95.00. They now have an “outperform” rating on the stock.
• 12/22/2025 – Cytokinetics had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/22/2025 – Cytokinetics had its price target raised by analysts at HC Wainwright from $120.00 to $136.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Barclays PLC from $82.00 to $87.00. They now have an “overweight” rating on the stock.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Cytokinetics had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a “market outperform” rating on the stock.
• 12/18/2025 – Cytokinetics was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a “buy” rating on the stock.
• 12/18/2025 – Cytokinetics was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $95.00 price target on the stock, up previously from $55.00.
• 12/12/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
• 12/1/2025 – Cytokinetics had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $61.00 price target on the stock.
• 11/11/2025 – Cytokinetics had its price target raised by analysts at Royal Bank Of Canada from $82.00 to $87.00. They now have an “outperform” rating on the stock.
• 11/10/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $90.00 price target on the stock, up previously from $80.00.
• 11/8/2025 – Cytokinetics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

Insider Transactions at Cytokinetics

In other news, EVP Andrew Callos sold 1,798 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $62.62, for a total value of $112,590.76. Following the completion of the sale, the executive vice president directly owned 50,440 shares of the company’s stock, valued at approximately $3,158,552.80. The trade was a 3.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Arthur Harrington sold 2,150 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $66.80, for a total transaction of $143,620.00. Following the sale, the director owned 18,542 shares of the company’s stock, valued at approximately $1,238,605.60. This represents a 10.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 153,649 shares of company stock valued at $9,987,132 over the last quarter. 3.40% of the stock is owned by corporate insiders.

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.